| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $5,530,700 ) |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA295874 | Proteotoxic Metabolites in Genome Instability and Disease | 000 | 1 | NIH | 11/12/2024 | $524,400 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS101880 | Molecular Determinants of Synaptic Plasticity in Chronic Pain | 000 | 8 | NIH | 11/21/2024 | $451,854 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS119162 | New Therapeutic Approaches for Stratified High-REST GBM Subtype | 000 | 5 | NIH | 11/21/2024 | $364,500 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255721 | Biology and novel therapy of AML expressing somatic or germline mutant RUNX1 | 000 | 5 | NIH | 11/13/2024 | $447,219 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL163857 | Premature aging disorders, metabolites, and atherosclerosis | 000 | 3 | NIH | 11/7/2024 | $641,069 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA275712 | Deciphering pathways involved in topoisomerase II turnover | 000 | 3 | NIH | 11/8/2024 | $452,669 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278971 | Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling | 000 | 2 | NIH | 11/7/2024 | $468,540 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279452 | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor | 000 | 2 | NIH | 11/7/2024 | $604,615 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K22CA279077 | Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics | 000 | 2 | NIH | 11/1/2024 | $192,240 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277152 | Preclinical studies of non-nucleoside DNMT3A/3B inhibitors | 000 | 2 | NIH | 11/1/2024 | $170,405 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA286992 | Targeting MDM4 in Rare Refractory Ovarian Cancer Sub-Types | 000 | 2 | NIH | 11/1/2024 | $204,485 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA260661 | Metabolic basis of ARID1A-mutated ovarian cancer | 000 | 4 | NIH | 11/1/2024 | $444,629 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03AI175719 | A somatic hypermutation defective UNG mutant in antibody deficiency through destabilization of RPA interaction. | 000 | 1 | NIH | 10/24/2024 | $0 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM134744 | Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms | 000 | 5 | NIH | 11/5/2024 | $0 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM153387 | A Functional Analysis of Arginine Methylation | 000 | 1 | NIH | 11/18/2024 | $0 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P50CA127001 | SPORE in Brain Cancer | 000 | 16 | NIH | 11/14/2024 | $0 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R33DA049334 | REST-mediated regulation of opioid receptors in chronic pain mouse models | 000 | 3 | NIH | 11/14/2024 | $10,932 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS126252 | Regulation of Peripheral Neuropathic Pain by B Cells | 000 | 3 | NIH | 11/12/2024 | $0 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE033330 | Advancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral Premalignancy | 001 | 2 | NIH | 11/13/2024 | $570,832 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM126929 | The molecular and genetic bases of diverse tissue repair responses in postembryonic Drosophila | 000 | 7 | NIH | 11/6/2024 | $0 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM130119 | Deciphering the hierarchical modularity of the mammalian cell through network integration and complex genetic perturbation strategies | 000 | 7 | NIH | 11/6/2024 | $0 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R25CA056452 | Cancer Prevention Education: Student Research Experiences | 000 | 31 | NIH | 11/1/2024 | $0 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM149226 | Regulation of Overall Cell Numbers During Epithelial Tissue Homeostasis and Pathogenesis | 000 | 2 | NIH | 11/5/2024 | $0 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U54CA274321 | The Houston Center for Acquired Resistance Research (H-CARR) | 000 | 3 | NIH | 10/25/2024 | $0 |
| | 2025 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P40OD010938 | Squirrel Monkey Breeding and Research Resource | 000 | 44 | NIH | 10/22/2024 | $0 |
| | 2025 | 2023 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA220236 | Wnt/?-catenin Signaling in Pancreatic Oncogenesis | 000 | 6 | NIH | 10/8/2024 | $992 |
| | 2025 | 2023 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37HD030284 | Female Reproductive Tract Development in the mouse | 000 | 30 | NIH | 10/16/2024 | -$53,602 |
| | 2025 | 2023 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MD013715 | A Randomized Controlled Trial of Mail-Self Stamped HPV Testing to Increase Cervical Cancer Screening Participation Among Minority/Underserved Women in an Integrated Safety Net Healthcare System | 002 | 6 | NIH | 11/14/2024 | $622,876 |
| | 2025 | 2023 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA174798 | Endothelial-to-osteoblast transition in prostate cancer bone metastasis | 000 | 10 | NIH | 11/15/2024 | $0 |
| | 2025 | 2023 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA237541 | Genomic and Transcriptomic Analysis of Mammographic Density | 000 | 5 | NIH | 10/18/2024 | $0 |
| | 2025 | 2023 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA231149 | Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5 | 000 | 5 | NIH | 10/21/2024 | -$1 |
| | 2025 | 2022 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS078152 | BK channel regulation by auxiliary LRR proteins | 000 | 10 | NIH | 10/15/2024 | $0 |
| | 2025 | 2022 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MH115717 | A phospho-switch in delta-catenin: relationship to PDZ-domain proteins and neuron development | 000 | 5 | NIH | 10/15/2024 | $0 |
| | 2025 | 2022 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DK118079 | Dynamic Prediction of Renal Failure Using Longitudinal Prognostic Information among Patients with Chronic Kidney Disease and Kidney Transplant | 000 | 4 | NIH | 10/9/2024 | -$30,720 |
| | 2025 | 2022 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE028290 | Administrative Supplement: Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac device | 000 | 4 | NIH | 11/19/2024 | $0 |
| | 2025 | 2022 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA225646 | Estimating the Cost Trajectories and Projecting the Cost of Cancer Care in the United States: Methodology and Application | 000 | 5 | NIH | 10/18/2024 | $0 |
| | 2025 | 2022 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21DE031082 | Diversity Supplement: Radiation-specific Automated Dental Dose Distributions via Machine-learning based Mapping for Accurate Predictions of (Peri)odontal Problems (RADMAP) | 001 | 2 | NIH | 10/28/2024 | -$4,503 |
| | 2025 | 2022 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21DE031082 | Diversity Supplement: Radiation-specific Automated Dental Dose Distributions via Machine-learning based Mapping for Accurate Predictions of (Peri)odontal Problems (RADMAP) | 000 | 2 | NIH | 10/28/2024 | -$9,391 |
| | 2025 | 2022 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA218230 | Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies | 000 | 5 | NIH | 10/29/2024 | $0 |
| | 2025 | 2022 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA252446 | Opioid-Sparing Interdisciplinary Interventions Addressing Pain in Head and Neck Cancer Patients | 000 | 2 | NIH | 10/21/2024 | $0 |
| | 2025 | 2021 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R33NS111058 | Evaluation of Novel Dually Targeted Kinase Inhibitors for Therapy of Adult and Pediatric High-Grade Glioma | 000 | 3 | NIH | 11/6/2024 | $0 |
| | 2025 | 2021 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61DA049334 | REST-mediated regulation of opioid receptors in chronic pain mouse models | 000 | 2 | NIH | 11/14/2024 | -$10,932 |
| | 2025 | 2021 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA240881 | Mitigating High Grade Radiation-Induced Lymphopenia through Pretreatment Autologous Lymphocyte Infusion | 000 | 2 | NIH | 10/8/2024 | -$39,666 |
| | 2025 | 2020 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA231506 | [18F]FAZA PET/CT for Monitoring Target Engagement of a Novel Complex I Inhibitor | 000 | 2 | NIH | 10/24/2024 | $0 |
| | 2025 | 2019 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | RF1NS113840 | Nrf2 Activation for Addiction-Free Treatment of Neuropathic Pain | 000 | 1 | NIH | 10/1/2024 | -$15,289 |
| | 2025 | 2019 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | RF1NS113256 | Dnmt3a as an epigenetic target for chronic pain treatment | 000 | 1 | NIH | 10/1/2024 | -$438,621 |
| | 2025 | 2019 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE029255 | Robust immunoprevention strategies for high-risk oral epithelial dysplasia | 001 | 2 | NIH | 10/1/2024 | -$4,570 |
| | 2025 | 2019 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE029255 | Robust immunoprevention strategies for high-risk oral epithelial dysplasia | 000 | 2 | NIH | 10/1/2024 | -$34,262 |
|
| Issue Date FY: 2024 ( Subtotal = $188,883,851 ) (Continued on the next page) |
|
